(Q35298399)

English

A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

based on heuristic

inferred from title

author name string

Friström B

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Nilsson SE

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

1 October 1997

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

British Journal of Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

81

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

867-870

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

27 July 2018

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

27 July 2018

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

27 July 2018

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

27 July 2018

Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

27 July 2018

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

27 July 2018

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

26 September 2018

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

26 September 2018

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1722025

26 September 2018

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9486028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/9486028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9486028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9486028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9486028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJO.81.10.867

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35298399&oldid=1638700402"